

1 **Severe COVID-19 induces molecular signatures of aging in the human**
2 **brain**

3

4 Maria Mavrikaki^{1, 4#}, Jonathan D. Lee^{1, 4}, Isaac H. Solomon² and Frank J. Slack^{1, 3#}

5

6 ¹Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School,
7 Boston, MA 02215, USA

8 ²Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
9 02215, USA

10 ³Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA 02215,
11 USA

12 ⁴These authors contributed equally: Maria Mavrikaki and Jonathan D. Lee

13

14 #Correspondence to M.M. and F.J.S.: mmavrika@bidmc.harvard.edu; fslack@bidmc.harvard.edu

15

16 **Abstract**

17 Coronavirus disease 2019 (COVID-19) is predominantly an acute respiratory disease caused by
18 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and remains a significant threat
19 to public health. COVID-19 is accompanied by neurological symptoms and cognitive decline, but
20 the molecular mechanisms underlying this effect remain unclear. As aging induces distinct
21 molecular signatures in the brain associated with cognitive decline in healthy populations, we
22 hypothesized that COVID-19 may induce molecular signatures of aging. Here, we performed
23 whole transcriptomic analysis of human frontal cortex, a critical area for cognitive function, in 12
24 COVID-19 cases and age- and sex-matched uninfected controls. COVID-19 induces profound
25 changes in gene expression, despite the absence of detectable virus in brain tissue. Pathway
26 analysis shows downregulation of genes involved in synaptic function and cognition and
27 upregulation of genes involved in immune processes. Comparison with five independent
28 transcriptomic datasets of aging human frontal cortex reveals striking similarities between aged
29 individuals and severe COVID-19 patients. Critically, individuals below 65 years of age exhibit
30 profound transcriptomic changes not observed among older individuals in our patient cohort. Our
31 data indicate that severe COVID-19 induces molecular signatures of aging in the human brain
32 and emphasize the value of neurological follow-up in recovered individuals.

33 **Introduction**

34 Although COVID-19 is primarily a respiratory disease, neurological symptoms are also
35 reported in a subpopulation of infected COVID-19 individuals [1], with substantially higher rates
36 (up to 84%) in severe COVID-19 cases [2]. For instance, patients with prior severe COVID-19
37 exhibit a 10-year average drop in their global cognitive performance [3]. Complementary studies
38 combining neuroimaging and cognitive screening implicate COVID-19-induced impairment of the
39 frontal cortex [4, 5], a critical area for cognitive function [6, 7]. Furthermore, the effects of COVID-
40 19 on the nervous system, including cognitive impairment, are expected to be long-term [3, 8-10].

41 However, the molecular mechanisms underpinning the effects of COVID-19 on cognition remain
42 to be determined.

43 In healthy populations, the natural process of aging leads to a reduction in frontal cortex
44 activity [11] and cognitive decline [12]. At the molecular level, aging induces distinct molecular
45 signatures in the human brain, including increased activation of immune signaling and decreased
46 synaptic activity [13-15]. Based on the deteriorating effects of COVID-19 on the frontal cortex and
47 on cognitive function, paralleling the effects of aging, we hypothesized that COVID-19 induces
48 molecular signatures of aging in the frontal cortex.

49 **COVID-19 gene expression in human brain**

50 To test this hypothesis, we performed whole transcriptomic analyses of postmortem frontal
51 cortex of 12 severe COVID-19 patients (with pre- or peri-mortem positive testing for SARS-CoV-
52 2 by nasopharyngeal swab qPCR and history of hospitalization) and 12 age- (± 2 years) and sex-
53 matched uninfected controls (**Fig. 1a**). Clustering analysis via t-distributed stochastic neighbor
54 embedding (TSNE) reveals separation of COVID-19-associated transcriptomic profiles from
55 control profiles (**Fig. 1b**), with the two controls proximal to COVID-19 cases being from elderly
56 patients (ages 71 and 84). To assess whether this clustering is due to the presence of SARS-
57 CoV-2 virus, we tested frontal cortex samples by quantitative PCR (qPCR) using two different
58 primer sets recommended by the Center for Disease Control and Prevention (**Fig. 1c**,
59 **Supplementary Fig. 1a**). No signal was detected above background noise for either of these
60 primer sets. Bioinformatic alignment of sequencing reads to the SARS-CoV-2 genome also did
61 not detect viral reads in COVID-19 or control samples (**Supplementary Fig. 1b**). In agreement
62 with previous studies [16, 17], our data show absence of detectable virus in the frontal cortex at
63 the time of death and suggest that the observed gene expression changes are not due to direct
64 effects of SARS-CoV-2 virus in the frontal cortex.

65 We next compared COVID-19 cases to their corresponding age- and sex-matched
66 controls and identified a total of 2,809 differentially expressed genes (DEGs) with unique Ensembl
67 gene IDs, 1,397 of which were upregulated and 1,412 downregulated (**Fig. 1d, Supplementary**
68 **Fig. 2a-b**). In the human brain, we did not observe expression of genes involved in SARS-CoV-2
69 entry, such as *ACE2* or *TMPRSS2* (**Supplementary Fig. 2c**) [8, 16]. On the other hand,
70 *S100A8/S100A9* genes, which encode for calprotectin and circulating levels of which distinguish
71 severe from mild COVID-19, were upregulated among COVID-19 patients in our cohort [18, 19].
72 In addition, *SYNGR1*, previously found to be downregulated in astrocytes and
73 monocytes/macrophages in the prefrontal cortex of severe COVID-19 patients [17], was also
74 downregulated in our cohort. Taken together, our analysis recapitulates many gene expression
75 findings previously associated with COVID-19.

76 To determine the functional roles of COVID-19 transcriptome-wide changes, we
77 performed pathway enrichment analysis using annotated Gene Ontology (GO) Biological
78 Processes (**Fig. 1e**). To our surprise, we found numerous significant DEGs and GO terms
79 associated with aging in the human brain to be significantly enriched upon severe COVID-19. In
80 agreement with previous studies [16, 17], we observed positive enrichment of immune response
81 terms (GO:0002376; GO:0002253) together with many immune-related genes upregulated in our
82 cohort (e.g., *BCL2*, *IFI16*, and *CFH*) (**Fig. 1e and Supplementary Fig. 3**). Of the top dysregulated
83 genes, we observed significant increases in *IFITM1-3* gene expression levels, which are
84 associated with interferon response [20]. Furthermore, we identified numerous synaptic function
85 terms to be negatively enriched, including synaptic signaling (GO:0099536), regulation of synaptic
86 plasticity (GO:0048167), and glutamatergic (GO:0035249), GABAergic (GO:0051932), and
87 dopaminergic (GO:0001963) synaptic transmission, with corresponding downregulation of
88 synaptic signaling genes (*SST*, *GRIA1*, and *GRIN2B*) (**Fig. 1e and Supplementary Fig. 3**).
89 Indeed, *SST*, one of the most downregulated genes in our COVID-19 cohort, has been previously

90 associated with aging in the human frontal cortex [14, 21]. We also observed significant
91 associations of cellular response to DNA damage (GO:0006974) [14, 22], mitochondrial function
92 (GO:0007005), regulation of response to stress (GO:0080134) and oxidative stress
93 (GO:0006979), vesicular transport (GO:0016192), calcium homeostasis (GO:0055074) [14],
94 apoptosis (GO:0042981) [23], and insulin signaling (insulin secretion: GO:0030073) [24-26]
95 pathways previously associated with aging processes and brain aging [14, 21]. Critically,
96 numerous COVID-19 DEGs are involved in cognitive function (cognition: GO:0050890; memory:
97 GO:0007613, GO:0007616; and learning or memory: GO:0007611). Assessment of the DEGs
98 overlapping with these enriched pathways reveals genes such as the brain-derived neurotrophic
99 factor (*BDNF*) which have been associated with aging [27, 28](**Fig. 1f**). KEGG and Reactome
100 pathway enrichment analyses also reveal positive enrichment of immune activation and negative
101 enrichment of synaptic function pathways (**Supplementary Fig. 4**). Interestingly, KEGG analysis
102 identifies the “Coronavirus Disease - COVID-19” pathway, based largely on non-brain tissue
103 effects of COVID-19, as one of the most significantly enriched pathways among COVID-19
104 patients (**Supplementary Fig. 4**). Altogether, our analyses suggest that many biological pathways
105 that change with natural aging in the brain also change in severe COVID-19.

106 **Molecular signatures of brain aging**

107 Based on the significant enrichment patterns of cognition pathways in COVID-19 brains,
108 together with the numerous enriched biological processes associated with aging, we sought to
109 test whether severe COVID-19 induces similarly widespread transcriptomic changes as aging in
110 the human frontal cortex. We collated transcriptome-wide datasets from five independent patient
111 cohorts assessing age-dependent changes in the frontal cortex (**Fig. 2a**). For all frontal cortex
112 aging datasets, genes upregulated in aging are upregulated in severe COVID-19; likewise, genes
113 downregulated in aging are also downregulated in severe COVID-19 (**Fig. 2b-c** and
114 **Supplementary Fig. 5**). Furthermore, a gene set previously associated with brain aging is

115 strongly upregulated in COVID-19 patients [29] (**Supplementary Fig. 6**). As additional support of
116 this association between frontal cortex aging and severe COVID-19, we confirmed upregulation
117 of *S100A9*, *MYL12A*, and *RHOBTB3* genes and downregulation of *CALM3*, *INPP4A*, *GRIA1*, and
118 *GRIN3A* in COVID-19 patients by qPCR, genes that are also differentially expressed in aged
119 frontal cortex (**Fig. 2d**). Thus, a substantial set of DEGs in aged frontal cortex are also differentially
120 expressed in the frontal cortex of severe COVID-19 patients.

121 Next, we sought to determine if the aging gene signature in the brain might differ between
122 younger (at or below 65 years of age, n=7/group) and older (above 65 years of age, n=5/group)
123 patients in our study cohort. To our surprise, we observed substantial transcriptomic changes
124 upon COVID-19 infection in the younger patient cohort, with minimal observable gene expression
125 changes in the older cohort (**Fig. 2e-f**). In older patients, COVID-19 upregulated the expression
126 of only 19 genes, including *HBB*, *HBA1* and *HBA2*, and downregulated the expression of 4 genes
127 (**Fig. 2f**). Among younger individuals (at or below 65 years of age), we identified 1,631
128 upregulated genes and 2,073 downregulated genes in COVID-19, with many of the same DEGs
129 from the age-/sex-matched full cohort also exhibiting significant differential expression.
130 Furthermore, these DEGs retain the same significant trends with aging-associated genes in the
131 frontal cortex (**Fig. 2g-h and Supplementary Fig. 7**). Altogether, our analyses suggest that the
132 brain aging effects of COVID-19 are far more pronounced in younger patients than in older
133 patients.

134 Finally, we tested whether the molecular changes in the brain induced by COVID-19 differ
135 between males (n=7/group) and females (n=5/group). We observed many significant DEGs in
136 both male (811 DEGs with unique Ensembl gene IDs; 396 were upregulated and 415 were
137 downregulated) and female (408 DEGs; 231 were upregulated and 177 were downregulated)
138 cohort subsets, including DEGs from our full cohort analysis (**Supplementary Fig. 8a-c**).
139 Furthermore, both males and females exhibit concordant changes in aging-associated genes and

140 pathways upon COVID-19 (**Supplementary Fig. 8d-e**). Thus, both males and females exhibit
141 aging-associated transcriptomic changes in the frontal cortex due to severe COVID-19.

142

143 **Discussion**

144 Several studies have been published assessing the transcriptomic changes induced by
145 severe COVID-19 in the human brain [16, 17, 30]. In agreement with our findings, single cell RNA-
146 seq studies of COVID-19 frontal cortex have identified increased immune activities [16, 17] and
147 decreased expression of genes involved in synaptic signaling [16], together with the absence of
148 detectable SARS-CoV-2 expression at the time of death [16, 17]. However, no study has yet
149 demonstrated the striking and profound similarities of transcriptomic profiles between COVID-19
150 disease and aging in the human brain. We believe this is for two reasons: (1) our patient cohort
151 was rigorously age- and sex-matched, and (2) the effects of COVID-19 on the brain are most
152 substantial among patients younger than 65 years of age, multiple of who are represented in our
153 cohort. Indeed, a recent RNA-seq study of the frontal cortex of COVID-19 individuals all above 67
154 years of age identified minimal transcriptomic changes (11 differentially expressed genes) [30].
155 Of the differentially expressed genes reported, we also observed *HBA1*, *HBA2*, and *HBB* genes
156 upregulated in our older patient cohort subset (>65 years of age). Further mechanistic
157 assessment of the brain aging-like profile observed among COVID-19 patients should thus be
158 focused on younger patient cohorts to capture these substantial transcriptomic effects.

159 We recognize limitations in our study design: the variability in illness duration, the
160 imperfect quality of several samples (as previously reported in similar studies [16]), the modest
161 number of subjects (12 cases and 12 controls), the lack of young COVID-19 subjects, and the
162 specificity of our findings due to COVID-19. Despite these constraints, we were sufficiently
163 powered to identify substantial transcriptome-wide changes between COVID-19 cases and

164 controls, including among younger patients in our patient cohort. Furthermore, in addition to being
165 age-matched, our experimental sample size is larger than previously reported COVID-19 brain
166 transcriptome studies [16, 17, 30], enabling the identification of aging-associated gene expression
167 signatures in our samples. Although our study does not examine the specificity of COVID-19-
168 induced transcriptomic changes in the brain, the implications of our findings may readily extend
169 to related pathologies. For instance, prior clinical trials have shown that cognitive impairment is
170 observed in 55% of survivors of severe acute respiratory syndrome (SARS) 12 months after
171 discharge [31]. Such behavioral observations suggest that similar molecular effects in the brain
172 may be observed not only in severe COVID-19 but also in other conditions characterized by
173 increased peripheral and central inflammation, severe hypoxic insults, and microvascular brain
174 pathologies [1, 32].

175 Aging is a major risk factor for the development of cognitive deficits and
176 neurodegenerative diseases [12, 33, 34]. Although the molecular changes in the brain upon
177 COVID-19 cannot be readily assessed in recovered individuals, our data herein suggest that
178 severe COVID-19 induces premature aging in the human brain, particularly among younger
179 individuals. Together with previously reported residual cognitive deficits observed in recovered
180 COVID-19 individuals [3], our results imply that increased long-term rates of cognitive decline and
181 neurodegenerative disorders may be observed among COVID-19 patients as a consequence of
182 long COVID. In light of this possibility, we advocate for neurological follow-up of recovered
183 COVID-19 patients and suggest potential clinical value in modifying risk factors to reduce the risk
184 or delay the development of aging-related neurological pathologies such as dementia [35].

185

186

187

188 **Acknowledgments**

189 This work was supported by a grant from the NIA (R01 AG058816) to F.J.S. We thank the National
190 Institutes of Health (NIH) NeuroBioBank, the Harvard Brain Tissue Resource Center (HBTRC),
191 and the Miami Brain Endowment Bank for providing control brain tissues. We also thank Dr.
192 Sabina Berretta, Director of the HBTRC, for advice on the selection of appropriate brain area
193 controls and Tanvi Saxena for advice on library preparation. We thank the BIDMC IBC and Robert
194 Griffin for advice on BL2+ protocols, Dr. Victoria Petkova for RNA-seq library quality control, and
195 Dr. Ioannis Vlachos for sequencing assistance.

196

197 **Author Contributions**

198 M.M. conceived of the idea and designed the study. M.M. performed the library preparation for
199 RNA-seq and qPCR experiments. J.D.L. performed bioinformatic analyses and generated all
200 relevant files including codes. I.H.S. generated the relevant IRB protocol, collected COVID-19
201 patient brain tissues, provided clinical annotations and determined the appropriate brain area for
202 the controls. F.J.S. and M.M. supervised the study. M.M., J.D.L. and F.J.S. wrote the manuscript.
203 All authors reviewed and edited the manuscript prior to submission.

204 **Declarations of interests**

205 The authors declare no conflicts of interest.

206

207 **Methods**

208 **Human brain tissues**

209 Post-mortem brain tissue specimens from individuals with severe COVID-19 were collected
210 through an excess tissue waived consent protocol approved by the Mass General Brigham
211 Institutional Review Board. Consent for autopsy was provided by the patients' next of kin
212 or healthcare proxy per Massachusetts state law. All autopsies were performed at Brigham and
213 Women's Hospital from 9/1/2020 to 3/30/2021 with pre- or peri-mortem positive testing for SARS-
214 CoV-2 by nasopharyngeal swab qPCR. COVID-19 cases had no known psychiatric or
215 neurological disorder (two cases had history of prior stroke). Tissues collected within a post-
216 mortem interval (PMI) less than 48 hours were included. At the time of autopsy, brains were
217 sectioned coronally, and samples of middle frontal gyrus (alternating between left and right sides
218 in the absence of gross abnormalities) were collected and frozen at -80°C. Frozen middle/superior
219 frontal gyrus (Brodmann area 8) controls were obtained from the NIH NeuroBioBank (Harvard
220 Brain Tissue Resource Center/HBTRC and the University of Miami's Brain Endowment Bank).
221 Controls were selected to be age- and sex-matched to a COVID-19 case and were categorized
222 as unaffected controls (with no known psychiatric or neurological condition) in the NIH
223 NeuroBioBank system. All controls were collected prior to the COVID-19 outbreak in the United
224 States (before 11/2019) and thus are considered uninfected by SARS-CoV-2. RNA integrity (RIN)
225 and PMI were not significantly different between groups.

226 Frozen tissue was processed using Biosafety Level 2+ (BL2+) procedures approved by
227 the Beth Israel Deaconess Medical Center (BIDMC) Institutional Biosafety Committee (IBC). Brain
228 tissues were homogenized using Trizol (Thermo Fisher) reagent and RNA extracted by phase
229 separation. Total RNA was quantified by nanodrop (DeNovix DS-11) and TapeStation 4200 (RNA
230 Screen Tape; Agilent Technologies, Inc).

231 **Library construction and RNA-sequencing**

232 450 ng of total RNA was used for library preparation via the KAPA RNA HyperPrep kit with
233 RiboErase (HMR; Roche) according to the manufacturer's recommendations. Briefly,
234 hybridization with hybridization oligos (HMR) was performed at 95 °C for 2 min followed by rRNA
235 depletion using RNase H which was performed at 45 °C for 30 min. Following rRNA cleanup via
236 KAPA pure beads, DNase digestion was performed at 37 °C for 30 min followed by cleanup, RNA
237 elution, fragmentation (6 min at 94°C for samples with RIN \geq 7 or 5 min at 85 °C for samples with
238 RIN \leq 7), and priming. First and second strand synthesis and A-tailing were performed according
239 to manufacturer's recommendations. 1.5 μ M KAPA Unique Dual-Indexed (UDI; Roche) adapters
240 were ligated to the second strand synthesis product in the presence of a ligation master mix in a
241 reaction that was performed at 20 °C for 15 min. Following cleanup, all libraries underwent 10
242 cycles of amplification. Successful library production, quality control, and quantification was
243 assessed using TapeStation (High sensitivity D1000 Screen Tape; Agilent Technologies, Inc). All
244 libraries were pooled together (10 nM concentration) and subjected to two lanes of a NovaSeq
245 6000.

246 **RT-qPCR (qPCR)**

247 A total of 400 ng RNA from each sample was processed for cDNA via SuperScript IV Reverse
248 Transcriptase kit (ThermoFisher Scientific) according to the manufacturer's instructions. All qPCR
249 experiments were performed in a 384-well plate using LightCycler 480 SYBR Green via a Roche
250 LightCycler 480 II PCR system.

251 To assess the expression of SARS-CoV-2, primers against the SARS-CoV-2 N1 and N2
252 genes were synthesized (IDT) as recommended by the US Center of Disease Control and
253 Prevention (CDC). The 2019-nCoV_N_Positive Control RUO Plasmid (IDT #10006625) was
254 included as positive control. *ITM2B* (Qiagen) was used for normalization. Primers for *S100A9*,

255 *RHOBTB3*, *MYL12A*, *CALM3*, *INPP4A*, *GRIA1*, and *GRIN3A* were designed to span exon-exon
256 junctions using NIH Primer Blast and synthesized by IDT. qPCR data were analyzed via the $2^{-\Delta\Delta C_t}$
257 method [36].

258 **RNA-seq analysis**

259 For assessment of SARS-CoV-2 genome alignment: reads were aligned to the SARS-CoV-2
260 reference genome (NCBI reference sequence NC_045512.2) using bowtie2 v2.2.9 with options
261 “-X 1000 --no-mixed”. Analysis of RNA-seq of Calu-3 infected samples from Blanco-Melo et al.
262 [37] were included as positive controls with default bowtie2 parameters.

263 For assessment of differential gene expression: raw sequencing reads were aligned to a
264 reference transcriptome generated from the Ensembl v104 human transcriptome with salmon
265 v1.4.0 using options “--seqBias --useVBOpt --gcBias --posBias --numBootstraps 30 --
266 validateMappings”. Length-scaled transcripts per million were acquired using the tximport v1.18.0
267 function, and log2 fold changes and false discovery rates (FDR) were determined by DESeq2
268 v1.30.1 in R. t-stochastic neighboring embedding analysis was performed using Rtsne v0.15, with
269 counts transformed by the varianceStabilizingTransformation (VST) function from DESeq2.
270 Heatmaps were generated using pheatmap v1.0.12 using VST-transformed counts, with further
271 scaling across samples. For full cohort analysis, age/sex-matching was used as a covariate. For
272 cohort subset analyses, no additional covariates were used.

273 **Gene set enrichment analysis**

274 Signed $-\log_{10}$ FDRs from DESeq2 analyses were used to rank genes for gene set enrichment
275 analysis via fgsea v1.16.0, filtering out genes with an FDR < 0.5. Public gene sets used for
276 analyses: Gene Ontology Biological Processes (GO.db v3.12.1), KEGG (KEGGREST v1.30.1),
277 and ReactomeDB (reactome.db v1.74.0) pathway to gene mappings from fgsea via the

278 “reactomePathways” function. For enrichment analyses, Ensembl gene IDs were matched with
279 corresponding gene symbols and Entrez IDs via biomaRt v2.46.3.

280 **Brain aging-regulated molecular signatures**

281 We leveraged previously published aging-regulated differentially expressed gene (DEG) set data
282 generated in five independent cohorts [14, 21, 38-41]. Lu et al. (2004) performed a broad-
283 spectrum gene expression analysis (Affymetrix Human Genome U95Av2) of human prefrontal
284 cortex from 30 individuals 26-106 years old and determined age-regulated genes based on a
285 comparison of individuals ≤ 42 vs individuals ≥ 73 years old [14]. Loerch et al. (2008) performed
286 a genome-wide gene expression analysis (Affymetrix Human Genome U133plus 2.0) of human
287 prefrontal cortex from 28 individuals 24-94 years old and determined age-regulated genes based
288 on a comparison of individuals ≤ 40 vs individuals ≥ 70 years old [21]. For three additional human
289 patient cohorts, we used differentially expressed genes as performed by [42] in which gene
290 expression data from individuals 85+ years old were compared to gene expression data of
291 younger individuals, including only individuals with annotated normal cognitive function. Those
292 cohorts include 1) the Gibbs et al. cohort [38] in which gene expression data (Illumina HumanRef-
293 8 Expression BeadChips) from the frontal cortex of 37 individuals were analyzed and DEGs
294 estimated by comparing individuals 85+ to individuals 55-80 years old [42]; 2) the ROSMAP
295 cohort, part of the Religious Order Study (ROS) and Rush Memory and Aging Project (MAP;
296 ROSMAP) at the Rush Alzheimer’s Disease Center [40, 41, 43], in which RNA-seq data from the
297 dorsolateral prefrontal cortex of 117 individuals were analyzed and DEGs estimated by comparing
298 individuals 85+ to individuals 70-80 years old [42]; and 3) the Common Mind Consortium (CMC)
299 cohort [39] in which RNA-seq data from the dorsolateral prefrontal cortex of 155 individuals were
300 analyzed and DEGs estimated by comparing individuals 85+ to individuals 60-80 years old [42].

301

302 **Statistical analysis**

303 No statistical methods were used to predetermine sample size. The experimental groups were
304 not randomized. Where possible, samples were processed together using deidentified numbers
305 (RNA-seq library preparation, reverse transcription prior to qPCR, and qPCR). For qPCR and
306 RNA-seq analyses, blinding was not possible as all changes had to be matched with
307 corresponding controls. qPCR data were analyzed with a two-tailed t-test via GraphPad Prism 9.
308 RNA-seq statistical analyses were performed in R v4.0.4 [44].

309 **Data availability**

310 RNA-seq fastq files generated for this study are available through GEO with accession number
311 GSE188847. Raw Calu-3 .fastq RNA-seq files from Blanco-Melo et al. are available through GEO
312 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147507>) with accession numbers
313 GSM4462348-GSM4462353 [37].

314 The SARS-CoV-2 genome was obtained from
315 <https://www.ncbi.nlm.nih.gov/nuccore/1798174254>. The Ensembl v104 human reference
316 transcriptome was obtained from [http://ftp.ensembl.org/pub/release-](http://ftp.ensembl.org/pub/release-104/fasta/homo_sapiens/cdna/Homo_sapiens.GRCh38.cdna.all.fa.gz)
317 [104/fasta/homo_sapiens/cdna/Homo_sapiens.GRCh38.cdna.all.fa.gz](http://ftp.ensembl.org/pub/release-104/fasta/homo_sapiens/cdna/Homo_sapiens.GRCh38.cdna.all.fa.gz). Gene Ontology
318 (<http://geneontology.org/>) was queried from org.Hs.eg.db v3.12.0 in R. Reactome pathway
319 annotations (<https://reactome.org/>) were obtained via the "reactomePathways" command in R
320 package "fgsea": <https://bioconductor.org/packages/release/bioc/html/fgsea.html>. KEGG hsa
321 pathway annotations (<https://www.genome.jp/kegg/>) were obtained using the KEGGREST
322 v1.30.1 API in R (<https://www.bioconductor.org/packages/release/bioc/html/KEGGREST.html>).

323

324

325 References

- 326 1. Solomon, I.H., et al., *Neuropathological Features of Covid-19*. N Engl J Med, 2020.
327 **383**(10): p. 989-992.
- 328 2. Helms, J., et al., *Neurologic Features in Severe SARS-CoV-2 Infection*. N Engl J Med,
329 2020. **382**(23): p. 2268-2270.
- 330 3. Hampshire, A., et al., *Cognitive deficits in people who have recovered from COVID-19*.
331 EClinicalMedicine, 2021. **39**: p. 101044.
- 332 4. Delorme, C., et al., *COVID-19-related encephalopathy: a case series with brain FDG-*
333 *positron-emission tomography/computed tomography findings*. Eur J Neurol, 2020.
334 **27**(12): p. 2651-2657.
- 335 5. Kas, A., et al., *The cerebral network of COVID-19-related encephalopathy: a longitudinal*
336 *voxel-based 18F-FDG-PET study*. Eur J Nucl Med Mol Imaging, 2021. **48**(8): p. 2543-
337 2557.
- 338 6. Miller, E.K., *The prefrontal cortex and cognitive control*. Nat Rev Neurosci, 2000. **1**(1): p.
339 59-65.
- 340 7. Ridderinkhof, K.R., et al., *The role of the medial frontal cortex in cognitive control*. Science,
341 2004. **306**(5695): p. 443-7.
- 342 8. Iadecola, C., J. Anrather, and H. Kamel, *Effects of COVID-19 on the Nervous System*.
343 Cell, 2020. **183**(1): p. 16-27 e1.
- 344 9. Hosp, J.A., et al., *Cognitive impairment and altered cerebral glucose metabolism in the*
345 *subacute stage of COVID-19*. Brain, 2021. **144**(4): p. 1263-1276.
- 346 10. Douaud, G., et al., *Brain imaging before and after COVID-19 in UK Biobank*. medRxiv,
347 2021.
- 348 11. Nyberg, L., et al., *Longitudinal evidence for diminished frontal cortex function in aging*.
349 Proc Natl Acad Sci U S A, 2010. **107**(52): p. 22682-6.

- 350 12. Bishop, N.A., T. Lu, and B.A. Yankner, *Neural mechanisms of ageing and cognitive*
351 *decline*. Nature, 2010. **464**(7288): p. 529-35.
- 352 13. Ham, S. and S.V. Lee, *Advances in transcriptome analysis of human brain aging*. Exp Mol
353 Med, 2020. **52**(11): p. 1787-1797.
- 354 14. Lu, T., et al., *Gene regulation and DNA damage in the ageing human brain*. Nature, 2004.
355 **429**(6994): p. 883-91.
- 356 15. Konar, A., P. Singh, and M.K. Thakur, *Age-associated Cognitive Decline: Insights into*
357 *Molecular Switches and Recovery Avenues*. Aging Dis, 2016. **7**(2): p. 121-9.
- 358 16. Yang, A.C., et al., *Dysregulation of brain and choroid plexus cell types in severe COVID-*
359 *19*. Nature, 2021. **595**(7868): p. 565-571.
- 360 17. Fullard, J.F., et al., *Single-nucleus transcriptome analysis of human brain immune*
361 *response in patients with severe COVID-19*. Genome Med, 2021. **13**(1): p. 118.
- 362 18. Saheb Sharif-Askari, N., et al., *Upregulation of oxidative stress gene markers during*
363 *SARS-COV-2 viral infection*. Free Radic Biol Med, 2021. **172**: p. 688-698.
- 364 19. Silvin, A., et al., *Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate*
365 *Severe from Mild COVID-19*. Cell, 2020. **182**(6): p. 1401-1418 e18.
- 366 20. Prelli Bozzo, C., et al., *IFITM proteins promote SARS-CoV-2 infection and are targets for*
367 *virus inhibition in vitro*. Nat Commun, 2021. **12**(1): p. 4584.
- 368 21. Loerch, P.M., et al., *Evolution of the aging brain transcriptome and synaptic regulation*.
369 PLoS One, 2008. **3**(10): p. e3329.
- 370 22. Yousefzadeh, M., et al., *DNA damage-how and why we age?* Elife, 2021. **10**.
- 371 23. Pollack, M., et al., *The role of apoptosis in the normal aging brain, skeletal muscle, and*
372 *heart*. Ann N Y Acad Sci, 2002. **959**: p. 93-107.
- 373 24. Boehm, M. and F. Slack, *A developmental timing microRNA and its target regulate life*
374 *span in C. elegans*. Science, 2005. **310**(5756): p. 1954-7.

- 375 25. Cholerton, B., L.D. Baker, and S. Craft, *Insulin resistance and pathological brain ageing*.
376 *Diabet Med*, 2011. **28**(12): p. 1463-75.
- 377 26. Smith-Vikos, T., et al., *MicroRNAs mediate dietary-restriction-induced longevity through*
378 *PHA-4/FOXA and SKN-1/Nrf transcription factors*. *Curr Biol*, 2014. **24**(19): p. 2238-46.
- 379 27. Primiani, C.T., et al., *Coordinated gene expression of neuroinflammatory and cell signaling*
380 *markers in dorsolateral prefrontal cortex during human brain development and aging*.
381 *PLoS One*, 2014. **9**(10): p. e110972.
- 382 28. Chapman, T.R., et al., *Aging and infection reduce expression of specific brain-derived*
383 *neurotrophic factor mRNAs in hippocampus*. *Neurobiol Aging*, 2012. **33**(4): p. 832 e1-14.
- 384 29. Soreq, L., et al., *Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of*
385 *Human Brain Aging*. *Cell Rep*, 2017. **18**(2): p. 557-570.
- 386 30. Gagliardi, S., et al., *Detection of SARS-CoV-2 genome and whole transcriptome*
387 *sequencing in frontal cortex of COVID-19 patients*. *Brain Behav Immun*, 2021.
- 388 31. Mikkelsen, M.E., et al., *The adult respiratory distress syndrome cognitive outcomes study:*
389 *long-term neuropsychological function in survivors of acute lung injury*. *Am J Respir Crit*
390 *Care Med*, 2012. **185**(12): p. 1307-15.
- 391 32. Lee, M.H., et al., *Microvascular Injury in the Brains of Patients with Covid-19*. *N Engl J*
392 *Med*, 2021. **384**(5): p. 481-483.
- 393 33. Hou, Y., et al., *Ageing as a risk factor for neurodegenerative disease*. *Nat Rev Neurol*,
394 2019. **15**(10): p. 565-581.
- 395 34. Inukai, S., et al., *Novel microRNAs differentially expressed during aging in the mouse*
396 *brain*. *PLoS One*, 2012. **7**(7): p. e40028.
- 397 35. Livingston, G., et al., *Dementia prevention, intervention, and care: 2020 report of the*
398 *Lancet Commission*. *Lancet*, 2020. **396**(10248): p. 413-446.
- 399 36. Schmittgen, T.D. and K.J. Livak, *Analyzing real-time PCR data by the comparative C(T)*
400 *method*. *Nat Protoc*, 2008. **3**(6): p. 1101-8.

- 401 37. Blanco-Melo, D., et al., *Imbalanced Host Response to SARS-CoV-2 Drives Development*
402 *of COVID-19*. Cell, 2020. **181**(5): p. 1036-1045 e9.
- 403 38. Gibbs, J.R., et al., *Abundant quantitative trait loci exist for DNA methylation and gene*
404 *expression in human brain*. PLoS Genet, 2010. **6**(5): p. e1000952.
- 405 39. Fromer, M., et al., *Gene expression elucidates functional impact of polygenic risk for*
406 *schizophrenia*. Nat Neurosci, 2016. **19**(11): p. 1442-1453.
- 407 40. Bennett, D.A., et al., *Overview and findings from the rush Memory and Aging Project*. Curr
408 Alzheimer Res, 2012. **9**(6): p. 646-63.
- 409 41. Bennett, D.A., et al., *Overview and findings from the religious orders study*. Curr Alzheimer
410 Res, 2012. **9**(6): p. 628-45.
- 411 42. Zullo, J.M., et al., *Regulation of lifespan by neural excitation and REST*. Nature, 2019.
412 **574**(7778): p. 359-364.
- 413 43. De Jager, P.L., et al., *A multi-omic atlas of the human frontal cortex for aging and*
414 *Alzheimer's disease research*. Sci Data, 2018. **5**: p. 180142.
- 415 44. Team, R.C., *R: A language and environment for statistical computing*. 2018, Vienna: R
416 Foundation for Statistical Computing.

417

418

419

420

421

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




Figure 1

422 **Fig 1. Severe COVID-19 induces global transcriptomic changes in the frontal cortex of the**
423 **brain. a.** Left, age and sex of each individual in COVID-19 or control groups (n=12/group)
424 analyzed in this cohort. Each COVID-19 case was matched with an uninfected control case by
425 sex and age (± 2 years). Right, schematic of study approach. *Schematic was generated with*
426 *BioRender.* **b.** t-distributed stochastic neighbor embedding (TSNE) analysis of frontal cortex
427 transcriptomes from COVID-19 cases and uninfected controls. **c.** qPCR assessment of SARS-
428 CoV-2 viral RNA in the frontal cortex using the nCoV_N1 primer set. PS1 and PS2 correspond
429 to the 2019-nCoV_N_Positive Control RUO Plasmid (IDT) at concentrations of 1,000 and 2,000
430 copies/ μ l, respectively (a technical duplicate/concentration was used to estimate the
431 corresponding mean; for control and COVID-19 samples n=13/group). **d.** Volcano plot
432 representing the differentially expressed genes (DEGs) of the frontal cortex of COVID-19 cases
433 versus matched controls. Red points, significantly upregulated genes among COVID-19 cases
434 (false discovery rate < 0.05). Blue points, significantly downregulated genes among COVID-19
435 cases. Black points, highlighted significant genes with corresponding gene symbols. **e.** Gene
436 ontology (GO) biological pathway enrichment analysis of COVID-19 versus control brain DEGs.
437 Gene ranks were determined by signed $-\log_{10}$ false discovery rates of DEGs. FDR, gene set
438 enrichment analysis false discovery rate. **f.** Heatmap of relative gene expression levels of
439 significant DEGs associated with the “cognition” (GO: 0050890) GO term across COVID-19 and
440 control samples. Color legend, scaled gene expression levels across subjects, normalized via
441 variance-stabilized transformation.

442

443





Figure 2

444 **Fig 2. Severe COVID-19 induces transcriptomic signatures of aging in the human brain. a.**
445 COVID-19-associated DEGs were assessed for enrichment of brain aging DEGs curated from
446 each of five independent patient cohort studies (Lu et al., 2004, n=21 [14]; Loerch et al., 2008,
447 n=28 [21]; Gibbs cohort, n=37 [38, 42]; ROSMAP cohort, n=117 [40-43], Common Mind
448 Consortium/CMC cohort, n=155 [39, 42]; n refers to the number of individuals analyzed in each
449 cohort). *Schematic was generated with BioRender.* **b** and **c.** Gene set enrichment analysis of
450 COVID-19 DEGs, using significantly up- (top) or down-regulated genes (bottom) in the Lu et al.
451 (2004) (**b**) and Loerch et al. (2008) (**c**) cohorts as gene sets. DEG ranks were assigned by signed
452 $-\log_{10}$ false discovery rates from COVID-19 versus control frontal cortex. NES, normalized
453 enrichment score. p, GSEA p-value. See also **Supplementary Fig. 5. d.** qPCR assessment of
454 candidate COVID-19 DEGs associated with aging (n=13/group). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.
455 Data are expressed as fold change relative to control \pm SEM. **e** and **f.** Volcano plots representing
456 the DEGs of the frontal cortex of COVID-19 cases versus controls among patients ≤ 65 (**e**,
457 n=7/group) or > 65 (**f**, n=5/group) years of age. Red points, significantly upregulated genes among
458 COVID-19 cases (false discovery rate < 0.05). Blue points, significantly downregulated genes
459 among COVID-19 cases. Black points, significant genes with corresponding gene symbols. **g** and
460 **h.** Gene set enrichment analysis of COVID-19 DEGs among individuals ≤ 65 years of age, using
461 significantly up- (left) or down-regulated genes (right) in the Lu et al. (2004) (**g**) and Loerch et al.
462 (2008) (**h**) cohorts as gene sets. DEG ranks were assigned by signed $-\log_{10}$ FDR values from
463 COVID-19 versus control brains among individuals ≤ 65 years of age. NES, normalized
464 enrichment score. p, GSEA p-value. See also **Supplementary Fig. 7.**

465




466 **Supplementary Figure 1. Assessment of SARS-CoV-2 virus in the postmortem human**
467 **frontal cortex and expression of SARS-CoV-2 brain entry-related genes. a.** qPCR
468 assessment of SARS-CoV-2 viral RNA in the frontal cortex using the nCOV_N2 primer set. PS1
469 and PS2 correspond to the 2019-nCoV_N_Positive Control RUO Plasmid (IDT) at concentrations
470 of 1,000 and 2,000 copies/ μ l, respectively (a technical duplicate/concentration was used to
471 estimate the corresponding mean; for control and COVID-19 samples n=13/group). **b.**
472 Percentages of RNA-seq reads aligning to the SARS-CoV-2 viral genome. SARS-COV-2 + and
473 SARS-COV-2 - correspond to Calu-3 lung cancer cell lines either infected with SARS-CoV-2 virus
474 or mock-infected, respectively [37] (n=3/group for the cell lines and n=12 for the control and
475 COVID-19 groups).

476


477

a


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



b



c




478 **Supplementary Figure 2. Overview of differential expression patterns in frontal cortex of**
479 **COVID-19 and uninfected subjects. a.** Age and sex matching used for differential expression
480 analysis. **b.** Heatmap of relative gene expression levels of all significant DEGs (FDR < 0.05)
481 across COVID-19 and control samples. Color legend, scaled gene expression levels across
482 subjects, normalized via variance-stabilized transformation. **c.** Heatmap of relative expression
483 levels of genes previously implicated in SARS-CoV-2 viral entry in the human brain [8] across
484 COVID-19 and control samples. Color legend, scaled gene expression levels across patients,
485 normalized via variance-stabilized transformation. Light gray cells, no aligned reads or genes
486 filtered out of analysis.

487

488


a

GO:0002253 activation of immune response



b


GO:0099536 synaptic signaling



489 **Supplementary Figure 3. Gene expression patterns of immune response activation and**
490 **synaptic plasticity pathways. a and b.** Heatmaps of relative gene expression levels of
491 significant DEGs associated with “activation of immune response” (GO: 0002253) (**a**) or
492 “synaptic signaling” (GO: 0099536) (**b**) GO terms across COVID-19 and control samples. Color
493 legend, scaled gene expression levels across subjects, normalized via variance-stabilized
494 transformation.

495

496



497 **Supplementary Figure 4. KEGG and Reactome pathway enrichment analyses. a and b.**


498 Kyoto Encyclopedia of Genes and Genomes (KEGG) (a) and Reactome (b) pathway enrichment

499 analysis of COVID-19 versus control brain DEGs. Gene ranks were determined by signed $-\log_{10}$

500 false discovery rates of DEGs. FDR, gene set enrichment analysis false discovery rate.

501


502



503 **Supplementary Figure 5. COVID-19 induces molecular signatures found at late age in the**
504 **human brain. a-c.** Gene set enrichment analysis of COVID-19 DEGs, using significantly up- (top)
505 or down-regulated genes (bottom) in the ROSMAP (a), Common Mind Consortium/CMC (b), and
506 Gibbs (c) cohorts as gene sets. DEG ranks were assigned by signed $-\log_{10}$ false discovery rates
507 from COVID-19 versus control subject frontal cortex. NES, normalized enrichment score. p, GSEA
508 p-value.

509


510



511 **Supplementary Figure 6. Gene expression patterns of a published brain aging gene**
512 **signature.** Heatmap of relative gene expression levels of a brain aging-distinguishing gene
513 signature from [29] across COVID-19 and control samples. Color legend, scaled gene expression
514 levels across subjects, normalized via variance-stabilized transformation.

515


516



517 **Supplementary Figure 7. COVID-19 induces molecular signatures found at late age in**
518 **individuals \leq 65 years of age. a-c.** Gene set enrichment analysis of COVID-19 DEGs among
519 individuals \leq 65 years of age, using significantly up- (top) or down-regulated genes (bottom) in
520 the ROSMAP (a), Common Mind Consortium/CMC (b), and Gibbs (c) cohorts as gene sets. DEG
521 ranks were assigned by signed $-\log_{10}$ false discovery rates from COVID-19 versus control subject
522 frontal cortex among individuals \leq 65 years of age. NES, normalized enrichment score. p, GSEA
523 p-value.

524

525



526 **Supplementary Figure 8. Aging effects of COVID-19 in male and female human brains. a.**
527 TSNE analysis of frontal cortex transcriptomes from COVID-19 cases and uninfected controls,
528 including sex annotations. **b** and **c**. Volcano plots representing the DEGs of the frontal cortex of
529 COVID-19 cases versus controls among males (**b**, n=7/group) or females (**c**, n=5/group). Red
530 points, significantly upregulated genes among COVID-19 cases (false discovery rate < 0.05). Blue
531 points, significantly downregulated genes among COVID-19 cases. Black points, significant
532 genes with corresponding gene symbols. **d** and **e**. Gene set enrichment analysis of COVID-19
533 DEGs among males (**d**) and females (**e**), using significantly up- (top) or down-regulated genes
534 (bottom) in the Lu et al. (2004) (left) and Loerch et al. (2008) (right) cohorts as gene sets. DEG
535 ranks were assigned by signed $-\log_{10}$ FDR values from COVID-19 versus control brains among
536 males and females. NES, normalized enrichment score. p, GSEA p-value.